Theriva Corp (TOVX) Long-Term Debt to Capital Ratio

Theriva Biologics, Inc. - graphic logo of issuer TOVX

Theriva Biologics, Inc. (TOVX) possesses significant market influence due to the development of unique adenoviruses that destroy tumors from within. This daily price chart for Theriva Biologics, Inc. (TOVX) reflects the asset's dynamics, with a metric of 0.25. The business relies on the creation of antiviral agents and microbiome correction within US laboratories. Meanwhile, the company minimizes operational risks by delegating clinical trials to specialized external contractors.

Long-Term Debt to Equity: Theriva Biologics, Inc. (TOVX) for 04/28/2023 - 11/01/2026

Analytical breakdowns for Theriva Biologics, Inc.

- market price and analyst price targets:
Market Price Theriva Biologics Inc|TOVX - Price Target Chart
- market capitalization details:
Market Capitalization Theriva Biologics, Inc.|TOVX - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Theriva Biologics|TOVX - Company Book Value|Market-to-Book Ratio therivabio.com|TOVX - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Theriva Biologics, Inc.|TOVX - Long-Term Debt to Equity|Current Liabilities to Capital therivabio.com|TOVX - Company Aggregate Debts|Debt to Net Assets Theriva Biologics, Inc.|TOVX - Company Long-Term Liabilities|Short-Term Debt Theriva Biologics|Intermediate Coverage Ratio therivabio.com
- company profitability and valuation multiples indicators:
TOVX - Net Profit
Summary company analysis:TOVX - Theriva Biologics Inc
Brand item of Synthetic Biologics

Theriva Biologics, Inc. (TOVX) invests in the development of oncolytic viruses and microbiome protection to combat cancer. This long-term financial debt sustainability indicator reflects the value of loans with maturities exceeding one year per unit of equity. The metric measures the company's reliance on external borrowing when implementing complex scientific projects. Low values confirm the autonomy of research funding, which reduces the risk of default during market shocks.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Janux Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RCUS (Arcus Biosciences, Inc.)|ZYME - Long-Term Debt to Equity Ratio|TNGX - Long-Term Debt to Equity|Long-Term Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity Compass Therapeutics|Long-Term Liabilities to Capital replimune.com REPL|Long-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Long-Term Indebtedness to Equity|Pyxis Oncology - Long-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Long-Term Liabilities to Capital|IOBT: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient STRO (sutrobio.com)|INKT: Long-Term Debt to Capital|HOWL - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Immix Biopharma Inc.|Long-Term Debt to Equity Ratio alxoncology.com (ALXO)|Long-Term Debt to Equity Cue Biopharma (CUE)|Long-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital MAIA Biotech MAIA|LIMN - Long-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Long-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Leap Therapeutics (LPTX)|Long-Term Debt to Equity Ratio INTS|SNSE - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc